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Objectives. This study examined the immediate angiographic 
and long-term clinical results of stenting saphenous vein graft 
aorto-ostial stenosis at a single center. 
Background. Data on the feasibility, safety and short- and 
long-term clinical results of stent implantation in aorto-ostial 
lesions in patients with unstable angina are limited. 
Methods. Paimaz or Palmaz-Schatz stents were deployed in 29 
patients (mean [-+SD] age 70 -+ 10 years) with complex (B2 or C) 
vein graft aorto-ostial lesion morphology. All patients had angina 
at rest; 23 (79%) had a previous myocardial infarction; and 13 
(45%) had two previous bypass operations (mean graft age 9 -+ 5 
years). Mean left ventricular ejection fraction was 42 -+ 13%. 
Results. Thirty-two stents were deployed in 25 new and 4 
restenotic aorto-ostial lesions. Ten additional stents were im- 
planted in five patients for eight lesions other than at ostial 
locations. Stent implantation was successful in all patients. There 
was no death, Q wave myocardial infarction, bypass surgery or 
stent hrombosis n the first 30 days. Stenting improved minimal 
lumen diameter f om 0.7 -+ 0.5 mm (95% confidence interval [CI] 
0.5 to 0.8) to 3.3 + 0.5 mm (CI 3.2 to 3.5) and percent diameter 
stenosis from 80 -+ 13% (CI 75% to 85%) to 1 -+ 12% (CI -3% to 
6%) (p < 0.001 for both variables). Immediate loss from recoil was 
0.2 -+ 0.2 mm (CI 0.2 to 0.3), corresponding to a percent recoil of 
7 -+ 5% (CI 5% to 9%). Clinical follow-up in all patients at a mean 
of 11 -+ 8 months revealed that 27 patients (94%) were free of 
death or myocardial infarction. Bypass surgery and balloon 
angioplasty were required in one (3%) and two (6%) patients, 
respectively. In 21 (88%) of the remaining 24 patients, symptoms 
were lessened by two or more symptom classes. 
Conclusions. Palmaz or Paimaz-Schatz stent implantation for 
saphenous vein graft aorto-ostial stenosis has a high likelihood of 
immediate success and is associated with a large immediate gain 
in lumen diameter. Thirty-day and long-term adverse event rates 
are low. These data suggest hat stenting saphenous vein graft 
aorto-ostial lesions is an acceptable therapeutic option in selected 
elderly patients with unstable angina and large-diameter vessels. 
(J Am Coil Cardiol 1995;25:866-70) 
Aorto-ostial location is an important predictor of early and late 
failure of conventional balloon angioplasty in both native 
arteries and saphenous vein grafts (1-6). Experience with 
second-generation interventional devices, including excimer 
laser coronary angioplasty and directional, rotational and 
extraction atherectomy, suggests that the once difficult to treat 
aorto-ostial lesion can be approached with a high probability of 
success and low complication rates (7-11). This notwithstand- 
ing, immediate lumen loss from recoil and late restenosis 
remains problematic. Coronary stenting of nonostial esions 
with the Palmaz-Schatz coronary stent is associated with the 
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largest immediate gain of any interventional device and has a 
low rate of restenosis (12). This report details our short-term 
and follow-up single-center xperience with Palmaz or Palmaz- 
Schatz stents implanted in saphenous vein graft aorto-ostial 
locations in a group of elderly patients with acute unstable 
ischemic syndromes. 
Methods  
Patients. Between March 1992 and June 1994, 29 patients 
(mean [+SD] age 70 + 10 years, range 45 to 84; 25 men [87%], 
4 women [13%]) had stents placed in aorto-ostial locations 
(-<3 mm from the vein graft vessel aortic origin) at Cedars- 
Sinai Medical Center. Patients were referred for this proce- 
dure if they had active ischemia related to the treated vessel; if 
they failed another intervention or were deemed suboptimal 
candidates for alternative treatment with other revasculariza- 
tion procedures, including bypass surgery; or if the target 
vessel was large enough to accept a stent ->3 mm in diameter, 
and there was adequate runoff. The demographics of the 
patient cohort are summarized in Table 1. Twelve patients 
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Table 1. Clinical Characteristics of 29 Study Patients 
Gender 
Male 25 (87%) 
Female 4 (13%) 
Mean age (yr) 70 _+ 10 
Range (yr) 45-84 
Risk factors for CAD 
Smoking 11 (38%) 
Hypertension 18 (62%) 
Diabetes 4 (14%) 
Hypercholesterolemia (>200 mg%) 11 (38%) 
Extent of CAD 
Prior MI 20 (69%) 
Recent MI 5 (17%) 
Prior multiple CABG 13 (45%) 
Mean graft age (yr) 9 + 5 
Range (yr) 1-20 
Mean LVEF (%) 42 _+ 13 
Range (%) 25-68 
Data presented are mean value _+ SD or number (%) of patients. CABG = 
coronary artery bypass operation; CAD - coronary artery disease; LVEF - left 
ventricular ejection fraction; MI - myocardial infarction. 
(41%) were >75 years old; 23 (79%) had a history of myocar- 
dial infarction, including 5 (17%) with recent (within 30 days) 
myocardial infarction; and 13 (45%) had undergone operation 
twice. Mean saphenous vein graft age was 9 + 5 years. All 
patients had multivessel coronary artery disease and presented 
to hospital with unstable angina (Canadian Cardiovascular 
Society class IV). Eleven (38%) patients had left ventricular 
failure. Mean left ventricular ejection fraction assessed by 
contrast ventriculography or gated blood pool radionuclide 
study in 25 (86%) patients was 42 +_ 13% (95% confidence 
interval [CI] 37% to 48%). 
Stent implantation. All patients had stenotic lesions 
(->50% diameter) involving the ostium of the vein graft vessel. 
All prestent lesions (25 new and 4 restenotic) were in morpho- 
logic class B2 (69%) or C (31%) according to the modified 
American College of Cardiology/American Heart Association 
criteria (3). One patient (3%) underwent rescue stenting in the 
setting of a suboptimal result after balloon angioplasty. Pa- 
tients received premedication with aspirin (325 rag/day) and 
dipyridamole (75 mg three times a day). Heparin was given 
during the procedure, maintaining the activated clotting time 
>300 s. 
A total of 42 stents were implanted (32 in ostial and 10 in 
nonostial locations), including 40 Palmaz-Schatz 15-mm artic- 
ulated stents and two 10-mm Palmaz biliary stents. Stents were 
deployed using the femoral approach, except one case where a 
brachial access was used. All lesions were predilated with 
undersized balloon catheters. Stents were positioned so that 
-1 mm of their proximal ends extended into the aortic root. 
After initial deployment, allstents were further expanded with 
large or high pressure balloons to leave a minimal residual 
stenosis. An oversized compliant balloon was used to flare the 
portion of the stent extending into the aorta. Continuous 
heparin infusion was started after arterial sheath removal and 
adjusted according to the activated partial thromboplastin me 
until oral anticoagulation therapy was stabilized. Antiplatelet 
and warfarin therapy were continued as previously recom- 
mended (13). 
Data analysis. All data were gathered prospectively in a 
registry data base. Cineangiograms were analyzed by a single 
experienced observer (E.R.) without previous knowledge of 
the clinical outcome. The severity of the stenosis was measured 
using an automated computer-assisted ge detection algo- 
rithm with magnification calibrated from the guiding catheter 
diameter (Imagecomm Systems), as reported elsewhere (7). 
The projection that best demonstrated the target lesion was 
selected throughout the study. End-diastolic frames with the 
most severe narrowing were selected, and the following mea- 
surements were obtained: 1) reference vessel diameter, 
2) minimal umen diameter, 3) lesion length, and 4) maximal 
balloon diameter after stent deployment. Percent diameter 
stenosis was calculated using the minimal and reference vessel 
diameters. Recoil was calculated as the difference of the 
maximal measured balloon diameter during stent deployment 
and the postprocedural minimal umen diameter divided by 
maximal balloon diameter. Procedure success was defined as 
successful stent deployment and residual stenosis <30% in the 
absence of major events during the hospital period (subacute 
thrombosis, bypass surgery, Q wave myocardial infarction, 
death) or a need for revascularization (target vessel or other) 
by surgical or catheter-based intervention during the first 30 
days. Serum creatine kinase (CK) levels were measured, and a 
12-lead electrocardiogram was obtained after the procedure 
and the next morning. Infarction was diagnosed if total CK 
level was >200 IU with positive (>5%) MB isoforms. 
Long-term clinical follow-up was obtained using a standard 
questionnaire, sent o the patient's physician or by return clinic 
visits. These data included the same adverse events and 
symptom classification (Canadian Cardiovascular Society clas- 
sification). Late stress tests were performed at the descretion 
of the referring physicians. Follow-up angiography was per- 
formed for clinical indications only. Restenosis was defined as 
->50% diameter narrowing at the stented aorto-ostial site. 
Statistical analysis. For all variables, data are presented as 
mean value _+ SD with 95% confidence interval (CI) values. 
Pairwise comparisons between variables were performed with 
the Student t test. A p value <0.05 was considered significant. 
Resu l ts  
Immediate r sults are summarized inTable 2. Single-lesion 
stent implantation was performed in 21 patients (72%). Eight 
procedures (28%) were multivessel or multilesion interven- 
tions. In five patients, 10 additional stents were deployed in 
eight lesions other than the ostial lesions, and in three other 
patients, four additional lesions were treated by balloon angio- 
plasty at the same setting. Single stents were placed in 26 ostial 
lesions (90%) and two overlapping stents in another 3 lesions 
(10%). In one patient (3%), stent implantation was indicated 
because of a suboptimal result of balloon angioplasty. Mean 
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Table 2. Angiographic Data Before and After Stenting 
Before stenting 
Lesion length (mm) 7.l _+ 2.8 
Reference vessel diameter ( am) 3.2 + 0.6 
MLD (mm) 0.7 _+ 0.5 
Percent diameter stenosis 80 _+ 13 
After stenting 
Reference vessel diameter (mm) 3.4 -- 0.4 
MLD (ram) 3.3 + 0.5 
Percent diameter stenosis 1 _+ 12 
Immediate gain (mm) 2.7 _+ 0.6 
Maximal balloon dilatation (ram) 3.6 _+ 0.5 
Maximal balloon pressure (atm) 11 + 4 
Recoil 
Amount (ram) 0.2 _+ 0.2 
Percent 7 _+ 5 
Data presented are mean value _+ SD. MLD - minimal umen diameter. 
maximal balloon pressure used for stent deployment was 11 + 
4 atm (CI 9 to 12). The balloon was usually inflated to 8 to 
10 atm, depending on the stent size and balloon diameter. In 
the last 15 patients (between July 1993 and June 1994), a 
relatively higher inflation pressure was used (12 _+ 5 atm) for 
stent deployment than that in the first 14 patients (10 _ 3 atm, 
p = NS). Stent implantation and procedural success was 
achieved in all 29 patients (100%) (Fig. 1). There were no 
major adverse vents, including subacute thrombosis, in the 
first 30 days. Vascular complications occurred in three patients 
(10%). One patient needed vascular epair, and two required 
blood transfusions. Non-Q wave myocardial infarction oc- 
curred in two patients (7%), which was presumed to result 
from distal embolization during the procedure. Peak CK levels 
were 282 and 345 IU. Duration of hospital stay after stent 
implantation averaged 5 _+ 2 days. Minimal lumen diameter 
increased more than fourfold, from a mean of 0.7 _+ 0.5 mm 
(CI 0.5 to 0.8) to 3.3 _+ 0.5 mm (CI 3.2 to 3.5, p < 0.001), and 
percent stenosis was improved from 80 _+ 13% (CI 75% to 
85%) to 1 + 12% (CI -3% to 6%, p < 0.001). Immediate 
lumen loss or recoil was 0.2 _+ 0.2 mm (CI 0.2 to 0.3), 
corresponding to 7 -+ 5% (CI 5% to 9%) relative recoil. 
Normal reference diameter increased significantly from 3.2 _+ 
0.6 mm (CI 2.9 to 3.4) before to 3.4 _+ 0.4 mm immediately 
after (CI 3.2 to 3.4) the procedure (p < 0.001). 
Clinical and angiographic follow-up. All 29 patients were 
followed up for a mean of 11 _+ 8 months (range 2 to 27). One 
patient (3%) died 8 months after stent implantation. The cause 
of death was related to progressive l ft heart failure without 
angiographic confirmation of the stented vessel patency. One 
patient (3%) had a myocardial infarction, and another (3%) 
required bypass reoperation (Fig. 2). Symptom- or stress 
testing-guided repeat angiography was performed in five 
patients (17%) at an average 5 _+ 2 months after stenting. 
Target vessel restenosis was found in four patients. Balloon 
angioplasty was successful in two patients and was not at- 
tempted in the two other patients where total occlusion was 
found. Of the 24 patients who were free of major adverse 
Figure 1. Top, Baseline right anterior oblique projection of a saphe- 
nous vein graft angiogram showing 96% stenosis of an eccentric 
aorto-ostial lesion. Bottom, Angiogram taken after deployment of a 
single Palmaz-Schatz coronary stent showing awidely patent vein graft 
(measured residual stenosis of 3%) to the left anterior descending 
coronary artery. 
clinical events or the need for repeat intervention, 8 (33%) 
were free of angina, 13 (55%) were in Canadian Cardiovascu- 
lar Society class I (n = 9) or II (n = 4), and 3 (12%) were in 
class III (n = 2) or IV (n = 1). 
Discuss ion 
This report documents a single center's experience with 
implantation ofslotted-tube stainless teel balloon-expandable 
stents in saphenous vein graft aorto-ostial stenoses in patients 
with unstable ischemic syndromes. The majority of patients 
were considered to be poor surgical candidates and at in- 
creased risk for a second or third bypass operation because of 
advanced age, poor left ventricular function or their general 
status. They represent a high-risk cohort of patients who may 
benefit he most from effective nonsurgical intervention. Our 
results demonstrate that stents can be placed in the aorto-ostial 
location with high primary success rate and paucity of peripro- 
cedure and long-term cardiac events in these high risk patients. 
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Late follow-up 11+8 months 
MI DEATH EVENT FREE PTCA CABG 
1/29(3%) 1/29(3%) 24/29(83%) 2/29(7%) 1/29(3%) 
ANGINA FREE CLASS I CLASS II CLASS III CLASS IV 
8/24{33%) 9124{38%) 4/24{17%) 2/24{8%) 1124{4%) 
Figure 2. Long-term follow-up and Canadian Cardiovascular Society 
angina class after stent deployment i  29 patients with unstable angina 
(angina class IV) with saphenous vein graft aorto-ostial lesions. 
CABG = coronary artery bypass grafting; MI = myocardial nfarction; 
PTCA = percutaneous transluminal coronary angioplasty. 
These results are encouraging when one considers the ad- 
vanced graft age (9 _+ 5 years) in this group of patients, the 
acuity of their clinical presentation and the placement of 
multiple stents in eight patients (28%). 
Treatment of aorto-ostial esions. Balloon angioplasty of 
aorto-ostial stenoses has a low primary success rate, a high 
complication rate and a high incidence of restenosis (1). The 
difficulty in treating these lesions stems largely from the 
apparent paradox that they tend to be both rigid and highly 
elastic (1). Several reports (7-12) have demonstrated that 
patients with aorto-ostial stenosis, apart from ostial left main 
coronary artery stenosis, are well suited for either excimer laser 
coronary angioplasty or directional or rotational atherectomy. 
The available data in peer-reviewed published reports (14-19) 
on stent implantation for aorto-ostial lesions have been based 
on experience with relatively few patients. To our knowledge, 
no randomized study comparing different treatment modalities 
has been published; therefore, no modality can conclusively be 
recommended for ostial lesions. Nevertheless, tents, when 
applicable, may be more effective than other devices in dimin- 
ishing the effect of elastic recoil as well as early and late 
restenosis (12,20,21). Stents appear best suited for discrete 
lesions in arteries ->3 mm in diameter that are balloon 
expandable. For rigid or nondilatable sions that resist effec- 
tive stent expansion, a reasonable strategy may be to debulk 
the lesion first with an atherectomy device or excimer laser. 
This combination has the potential of achieving alarger lumen 
dimension than balloon angioplasty or debulking devices used 
alone. 
Effectiveness of stenting saphenous vein graft aorto-ostial 
lesions. The mechanical dvantages ofstenting may be ideally 
suited for the aorto-ostial saphenous vein graft lesion. In the 
present study, the immediate gain in diameter was 2.7 _+ 
0.6 mm, with only 7% loss from immediate r coil responsible 
for an average 0.2-mm loss in lumen diameter. This compares 
favorably with excimer laser balloon angioplasty insimilar vein 
graft lesions with identical reference diameters (3.4 -+ 1.1 mm) 
and relatively shorter lesion lengths (4.1 _+ 4.3 mm), where 
procedural success was 91%, estimated recoil 35% (1 mm of 
immediate loss), immediate gain 1.3 -+ 0.5 mm and residual 
stenosis 36 _+ 15% (7). Our present data suggest that these 
stents are sufficiently crush-resistant to overcome the increased 
elasticity and external stent compression of the aorto-ostial 
junction. 
Subacute thrombosis till remains a major limitation of 
stent implantation. None of our patients had early stent 
thrombosis, and, consequently, no potential difference in 
thrombosis rate between patients treated with single versus 
multiple stents could have been detected. This may be related 
to the achievement of optimal stent expansion and selection of 
patients with relatively large vessels with brisk runoff. A recent 
report (22) suggests that prolonged anticoagulation with hep- 
arin and warfarin may not be necessary insuch patients, which 
could potentially decrease the 5-day length of stay and the 10% 
incidence of bleeding and vascular complications reported 
here. However, it is not inconceivable that stenting an aorto- 
ostial lesion warrants a longer period of anticoagulation in 
view of slight stent protrusion into the aorta and the potential 
for producing systemic thromboemboli. Although there was no 
such episode in our patients with aorto-ostial lesions, we 
believe that a larger study is needed to determine whether the 
current herapeutic protocol is adequate to minimize this risk. 
Late follow-up revealed that 26 (90%) of 29 patients who 
underwent s enting were free of adverse major events (death, 
infarction or bypass surgery) at a mean of 12 _+ 9 months. 
Repeat balloon angioplasty was performed in two patients 
(7%). In 21 (88%) of the 24 remaining patients, symptoms 
lessened by two or more symptom classes (Fig. 2). These 
results are consistent with other eports of stents applied to the 
body of vein grafts (23) and compare favorably with other new 
devices for treatment of this anatomic subgroup. 
Study limitations. Our study is subject o several imita- 
tions that should be considered when interpreting the results. 
First, this was a study of a relatively small number of highly 
selected patients, and thus there are insufficient data to 
comment on factors responsible for failure and complications. 
Second, this was a single-center study, which reflects our bias 
toward patient selection, technique and our learning curve. 
Third, our patients with aorto-ostial lesions cannot necessarily 
be rigorously compared with reports of treatment with other 
devices, especially those applied predominantly to native le- 
sions in arteries <3 mm in diameter. Finally, the incidence of 
angiographic restenosis was not assessed and cannot be pre- 
dicted from the low rate of angiographic follow-up (24). 
Summary. The study limitations notwithstanding, there are 
several clinical inferences that can be drawn from our experi- 
ence. Stent implantation i aorto-ostial saphenous vein graft 
lesions has a high likelihood of procedural success with rela- 
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tively low morbidity and infrequent late adverse clinical events. 
It is an effective therapeutic option in high risk, elderly patients 
with unstable ischemic syndromes after bypass surgery who 
may gain early and long-term clinical benefit from this treat- 
ment strategy. Stent implantation results in a very large 
immediate gain with minimal elastic recoil and hence repre- 
sents a potential advance over other interventional techniques. 
In view of the current data, our own treatment s rategy would 
be to consider primary stenting for aorto-ostial lesions in 
_>3-mm diameter vein grafts. In vein grafts or native arteries 
-<3 ram, we would consider treatment with a debulking device 
and adjunctive balloon angioplasty. In native arteries that are 
rigid or calcified and ->3 ram, we would consider first the 
debulking-angioplasty approach and apply a slotted-tube stent 
when a minimal lumen diameter of 2 mm could not be 
achieved or if significant dissection is seen. Careful consider- 
ation of risk/benefit ratio and health care costs should also be 
factored into the decision process with regard to stent implan- 
tation, repeat operation or treatment with other angioplasty 
devices. 
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